 |
PDBsum entry 1hv5
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of the stromelysin-3 (mmp-11) catalytic domain complexed with a phosphinic inhibitor
|
|
Structure:
|
 |
Stromelysin 3. Chain: a, b, c, d, e, f. Synonym: matrix metalloproteinase 11, mmp-11, st3, sl-3. Engineered: yes
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Gene: stro3 (101-264). Expressed in: escherichia coli bl21. Expression_system_taxid: 511693.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.60Å
|
R-factor:
|
0.218
|
R-free:
|
0.262
|
|
|
Authors:
|
 |
A.L.Gall,M.Ruff,R.Kannan,P.Cuniasse,A.Yiotakis,V.Dive,M.C.Rio, P.Basset,D.Moras
|
Key ref:
|
 |
A.L.Gall
et al.
(2001).
Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state.
J Mol Biol,
307,
577-586.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
08-Jan-01
|
Release date:
|
28-Mar-01
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q02853
(MMP11_MOUSE) -
Stromelysin-3 from Mus musculus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
492 a.a.
162 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
307:577-586
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state.
|
|
A.L.Gall,
M.Ruff,
R.Kannan,
P.Cuniasse,
A.Yiotakis,
V.Dive,
M.C.Rio,
P.Basset,
D.Moras.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Stromelysin-3 (ST3) is a matrix metalloproteinase (MMP-11) whose proteolytic
activity plays an important role in tumorigenicity enhancement. In breast
cancer, ST3 is a bad prognosis marker: its expression is associated with a poor
clinical outcome. This enzyme therefore represents an attractive therapeutic
target.The topology of matrix metalloproteinases (MMPs) is remarkably well
conserved, making the design of highly specific inhibitors difficult. The major
difference between MMPs lies in the S(1)' subsite, a well-defined hydrophobic
pocket of variable depth. The present crystal structure, the first 3D-structure
of the ST3 catalytic domain in interaction with a phosphinic inhibitor mimicking
a (d, l) peptide, clearly demonstrates that its S(1)' pocket corresponds to a
tunnel running through the enzyme. This open channel is filled by the inhibitor
P(1)' group which adopts a constrained conformation to fit this pocket, together
with two water molecules interacting with the ST3-specific residue Gln215. These
observations provide clues for the design of more specific inhibitors and show
how ST3 can accommodate a phosphinic inhibitor mimicking a (d, l) peptide.The
presence of a water molecule interacting with one oxygen atom of the inhibitor
phosphinyl group and the proline residue of the Met-turn suggests how the
intermediate formed during proteolysis may be stabilized. Furthermore, the
hydrogen bond distance observed between the methyl of the phosphinic group and
the carbonyl group of Ala182 mimics the interaction between this carbonyl group
and the amide group of the cleaved peptidic bond. Our crystal structure provides
a good model to study the MMPs mechanism of proteolysis.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Crystal structure of the stromelysin-3 catalytic
domain complexed with the phosphinic inhibitor. (a) Ribbon
diagram showing the catalytic domain of ST3 (blue), the
phosphinic inhibitor (pink), the two zinc atoms (red spheres)
and the calcium atom (blue sphere). The Figure was created with
Setor.[45] (b) The molecular surface of the ST3 catalytic domain
is coloured according to its potential (red: negatively charged
residues; blue, positively charged residues). The catalytic zinc
atom (green) lies on the surface of the active site. The Figure
was created with GRASP. [46]
|
 |
Figure 4.
Figure 4. Inhibitor binding mode. (a) The molecular surface
of the ST3 active site. The catalytic zinc atom (green) lies on
the surface. The figure was created with GRASP.[46] (b) The
S[1]' pocket is a deep cavity filled by the P[1]' group of the
phosphinic inhibitor RXP03 and two water molecules (blue
spheres). The ST3 surface (in yellow) is coloured in green at
the position of Gln215. The Figure was created with DINO (DINO:
Visualizing Structural Biology developped by Ansgar Philippsen;
http://www.bioz.unibas.ch/ not, vert, similar- xray/dino).
(c) Final 2F[obs] -F[calc] electron density map (white) in the
ST3 active site, contoured at 1.0 sigma. Two of the three His
side-chains ligating the catalytic zinc atom (red sphere) are
represented. The phosphinic inhibitor is coloured in pink. The
Figure was created with Setor.[45]
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2001,
307,
577-586)
copyright 2001.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.B.Fields
(2010).
Synthesis and biological applications of collagen-model triple-helical peptides.
|
| |
Org Biomol Chem,
8,
1237-1258.
|
 |
|
|
|
|
 |
I.Bertini,
M.Fragai,
C.Luchinat,
M.Melikian,
E.Mylonas,
N.Sarti,
and
D.I.Svergun
(2009).
Interdomain Flexibility in Full-length Matrix Metalloproteinase-1 (MMP-1).
|
| |
J Biol Chem,
284,
12821-12828.
|
 |
|
|
|
|
 |
J.Lauer-Fields,
K.Brew,
J.K.Whitehead,
S.Li,
R.P.Hammer,
and
G.B.Fields
(2007).
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.
|
| |
J Am Chem Soc,
129,
10408-10417.
|
 |
|
|
|
|
 |
M.Matziari,
V.Dive,
and
A.Yiotakis
(2007).
Matrix metalloproteinase 11 (MMP-11; stromelysin-3) and synthetic inhibitors.
|
| |
Med Res Rev,
27,
528-552.
|
 |
|
|
|
|
 |
I.Bertini,
V.Calderone,
M.Fragai,
C.Luchinat,
M.Maletta,
and
K.J.Yeo
(2006).
Snapshots of the reaction mechanism of matrix metalloproteinases.
|
| |
Angew Chem Int Ed Engl,
45,
7952-7955.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.F.Fisher,
and
S.Mobashery
(2006).
Recent advances in MMP inhibitor design.
|
| |
Cancer Metastasis Rev,
25,
115-136.
|
 |
|
|
|
|
 |
L.Devel,
V.Rogakos,
A.David,
A.Makaritis,
F.Beau,
P.Cuniasse,
A.Yiotakis,
and
V.Dive
(2006).
Development of selective inhibitors and substrate of matrix metalloproteinase-12.
|
| |
J Biol Chem,
281,
11152-11160.
|
 |
|
|
|
|
 |
A.L.Gall,
M.Ruff,
and
D.Moras
(2003).
The dual role of CHAPS in the crystallization of stromelysin-3 catalytic domain.
|
| |
Acta Crystallogr D Biol Crystallogr,
59,
603-606.
|
 |
|
|
|
|
 |
W.Bode,
and
K.Maskos
(2003).
Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
|
| |
Biol Chem,
384,
863-872.
|
 |
|
|
|
|
 |
W.Pan,
M.Arnone,
M.Kendall,
R.H.Grafstrom,
S.P.Seitz,
Z.R.Wasserman,
and
C.F.Albright
(2003).
Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display.
|
| |
J Biol Chem,
278,
27820-27827.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |